Alteogen Announces 20 Billion Won Cash Dividend...First Since Its Establishment

Alteogen announced on the 11th that its board of directors had resolved to pay a cash dividend totaling 20 billion won. The company will pay 371 won per share for both common and preferred stocks.

This is the first dividend since Alteogen was founded. The decision was made to share the company’s achievements with shareholders and enhance shareholder value. Since turning profitable in 2024, Alteogen has strengthened its financial base through expanded technology exports and product approvals obtained via partnerships. Last year, on a standalone basis, the company posted sales of 201.1 billion won and operating profit of 114.8 billion won, marking the highest performance since its establishment.

Bird's-eye view of Alteojen headquarters and research center in Daejeon. Alteojen

원본보기 아이콘

Keytruda in subcutaneous (SC) formulation, developed using Alteogen’s Hybrozyme platform technology, has obtained J-code and European marketing authorization following its U.S. market launch in September last year. Alteogen expects that, as the switch from the existing intravenous (IV) formulation to the SC formulation gradually expands, milestone income will also increase. Based on this sustainable growth, the company plans to continue implementing its shareholder return policy.

Alteogen CEO Jeon Taeyeon said, "We are pleased to share the company’s profits with our shareholders through this first dividend," adding, "We will work to strengthen our performance and financial soundness through a stable revenue base and expanded partnerships, and to consistently continue our shareholder return efforts."

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.